
Amgen Inc‘s (NASDAQ:AMGN) second quarter results demonstrate ongoing development of its late-stage pipeline “to offset end-of-decade losses-of-exclusivity," according to Goldman Sachs.
The Amgen Analyst: Goldman Savhs analyst Salveen Richter reiterated a Buy rating, while raising the price target from $400 to $405.